{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T01:03:22Z","timestamp":1724029402303},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.7759\/cureus.51528","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:04:42Z","timestamp":1704211482000},"source":"Crossref","is-referenced-by-count":1,"title":["Hypofractionated Radiotherapy as a Standalone Treatment Modality for Locally Advanced Type B2 Thymoma in an Octogenarian Patient: 45 Gy in 15 Fractions"],"prefix":"10.7759","author":[{"given":"Atsuto","family":"Katano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Minamitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.06.011","article-title":"Molecular landscape of thymic epithelial tumors","volume":"39","author":"Prays J","year":"2022","unstructured":"Prays J, Ortiz-Villal\u00f3n C. Molecular landscape of thymic epithelial tumors. Semin Diagn Pathol. 2022, 39:131-6. 10.1053\/j.semdp.2021.06.011","journal-title":"Semin Diagn Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10619-6","article-title":"The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma","volume":"23","author":"Li H","year":"2023","unstructured":"Li H, Ren B, Yu S, Gao H, Sun PL. The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma. BMC Cancer. 2023, 23:161. 10.1186\/s12885-023-10619-6","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02788-w","article-title":"SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)","volume":"24","author":"Remon J","year":"2022","unstructured":"Remon J, Bernab\u00e9 R, Diz P, et al.. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clin Transl Oncol. 2022, 24:635-45. 10.1007\/s12094-022-02788-w","journal-title":"Clin Transl Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Girard N","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015, 26 Suppl 5:v40-55. 10.1093\/annonc\/mdv277","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14847","article-title":"Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors","volume":"14","author":"Xu C","year":"2023","unstructured":"Xu C, Zhang Y, Wang W, et al.. Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors. Thorac Cancer. 2023, 14:1102-17. 10.1111\/1759-7714.14847","journal-title":"Thorac Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.12.045","article-title":"Intensity modulated radiation therapy plus etoposide\/cisplatin for patients with limited advanced unresectable thymic epithelial tumors: a prospective phase 2 study","volume":"107","author":"Fan XW","year":"2020","unstructured":"Fan XW, Yang Y, Wang HB, et al.. Intensity modulated radiation therapy plus etoposide\/cisplatin for patients with limited advanced unresectable thymic epithelial tumors: a prospective phase 2 study. Int J Radiat Oncol Biol Phys. 2020, 107:98-105. 10.1016\/j.ijrobp.2019.12.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58692-2","article-title":"Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma","volume":"10","author":"Fan C","year":"2020","unstructured":"Fan C, Ge H, Zhang S, et al.. Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma. Sci Rep. 2020, 10:1735. 10.1038\/s41598-020-58692-2","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202012_24044","article-title":"COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine","volume":"24","author":"Di Franco R","year":"2020","unstructured":"Di Franco R, Borzillo V, D'Ippolito E, et al.. COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine. Eur Rev Med Pharmacol Sci. 2020, 24:12480-9. 10.26355\/eurrev_202012_24044","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.02.009","article-title":"How low can you go? The radiobiology of hypofractionation","volume":"34","author":"Brand DH","year":"2022","unstructured":"Brand DH, Kirby AM, Yarnold JR, Somaiah N. How low can you go? The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2022, 34:280-7. 10.1016\/j.clon.2022.02.009","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/219522-hypofractionated-radiotherapy-as-a-standalone-treatment-modality-for-locally-advanced-type-b2-thymoma-in-an-octogenarian-patient-45-gy-in-15-fractions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:13:14Z","timestamp":1707509594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/219522-hypofractionated-radiotherapy-as-a-standalone-treatment-modality-for-locally-advanced-type-b2-thymoma-in-an-octogenarian-patient-45-gy-in-15-fractions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.51528","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,2]]}}}